Lunsekimig Shows Promise in Asthma and CRSwNP—But Falls Short in Atopic Dermatitis

The next wave of respiratory biologics is here. And it’s getting smarter. Sanofi has released Phase 2 data for lunsekimig, a next-generation bispecific Nanobody. The results are mixed—but strategically significant. Let’s break it down.

The Big Idea: One Drug, Two Targets

Traditional biologics target a single inflammatory pathway. Lunsekimig does something different. It simultaneously blocks:

• TSLP → an upstream trigger of inflammation
• IL-13 → a downstream driver of tissue damage

This dual-action approach aims to shut down inflammation at multiple levels.

Translation: Instead of patching leaks, it tries to turn off the main valve.

Phase 2 Results: Where Lunsekimig Wins

1. Asthma (AIRCULES Study – Phase 2b)

Population: Moderate-to-severe asthma patients
Outcome: Strong success

Key results:

• Significant reduction in asthma exacerbations
• Improved lung function (pre-BD FEV1)
• Benefits observed across different biomarker profiles (FeNO, eosinophils)

Why this matters:

• Over 50% of asthma patients remain uncontrolled
• Exacerbations drive hospitalizations and healthcare costs

Lunsekimig directly targets this gap.

2. Chronic Rhinosinusitis with Nasal Polyps (DUET Study – Phase 2a)

Outcome: Clear success

Key improvements:

• Reduced nasal polyp size
• Better nasal congestion scores
• Improved CT scan results (Lund-Mackay score)

Clinical insight:

• Many CRSwNP patients also have asthma
• A dual-indication biologic could be a major advantage

Where It Struggled: Atopic Dermatitis (VELVET Study – Phase 2b)

Not everything worked.

Primary endpoint: Missed

• No significant improvement in EASI score

But secondary endpoints: Positive signals

• EASI-75 (≥75% improvement) improved
• vIGA-AD 0/1 (clear/almost clear skin) improved

Interpretation:

• The drug shows activity—but not strong enough (yet)
• Dose optimization or patient selection may be needed

Safety Profile: Clean and Consistent

Across all studies, lunsekimig was generally well tolerated.

Most common side effects:

• Nasopharyngitis
• Upper respiratory infections
• Headache
• Injection site reactions

Important note:

• Serious adverse events were similar to placebo
• No major safety red flags

Why Lunsekimig Is Different?

This isn’t just another biologic.

Key differentiators:

• Bispecific mechanism → targets two pathways
• Pentavalent Nanobody design → five linked antibody fragments
• Albumin binding → longer half-life

If successful, lunsekimig could:

• Reduce dosing frequency
• Improve efficacy vs single-target biologics
• Expand across multiple immune diseases

What’s Next: Moving Into Phase 3?

Development is moving fast. Ongoing studies include:

• AIRLYMPUS (Phase 2) → high-risk asthma
• PERSEPHONE (Phase 3) → asthma
• THESEUS (Phase 3) → asthma

Regulatory approval is still pending.

Market Context: A Massive Opportunity

Asthma

• ~262 million patients globally
• More than half remain uncontrolled

CRSwNP

• Chronic, quality-of-life–driven disease
• Strong overlap with asthma

Takeaway: There’s a clear unmet need—and room for better biologics.

Final Take: Promising, But Not Perfect

Lunsekimig is a classic case of targeted innovation with early validation.

What’s working:

• Strong efficacy in asthma
• Clear benefit in CRSwNP
• Solid safety profile

What’s uncertain:

• Inconsistent performance in skin disease
• Long-term efficacy vs existing biologics

The Strategic Lens

Here’s the bigger picture:

• Dual-targeting biologics are gaining traction
• Precision immunology is becoming the norm
• Companies like Sanofi are betting on multi-pathway control

If Phase 3 confirms these results, lunsekimig could become: A first-in-class, multi-indication respiratory biologic. And that’s a big deal.